Renta 4 | The FDA has given the green light to expand the use of Moderna’s vaccine for the treatment of RSV, the virus that causes bronchiolitis, in adults aged 18 to 59. This vaccine has already been approved by both the EMA and the FDA for use in adults over 60, as well as in the United Kingdom, Australia and Taiwan. Given Rovi’s agreement with the US pharmaceutical company,…
Bankinter: After a long process of inspection of its factories, the Company has obtained this authorisation, which makes it possible to manufacture in Spain and sell in the United States Moderna’s anti-COVID vaccine and a next generation of vaccines that Moderna plans to introduce in the market based on the same technology. Assessment: Very positive news that improves the outlook for Rovi’s third party manufacturing, which already represents approximately 50%…
Four months ago, Spanish ROVI reached an agreement with Moderna for the filling and packaging of its vaccine. Since then ROVI’s capitalisation has increased by more than €750 M (up 53%). So far this month alone, the stock price has risen by 27%. With a central scenario of about 550 M of Moderna’s vaccines per year outside the US and Japan, the unit income for ROVI would be 0.75 €/vaccine (3.5% higher than the total price of the vaccine) which means a T.P. rise of +6, 5 €/shr. (+22% vs. before) up to 36 €/acc.
US biotech firm Moderna and Spanish laboratory Rovi announced a collaboration agreement to carry out the filling and finishing of a candidate vaccine for Covid-19 (mRNA-1273) outside the US. ROVI will carry out the phases of vial filling and completion. Thus it will acquire a new production line and the necessary equipment for formulation, filling, inspection and labelling, as well as the additional personnel required.The new line would be owned by Rovi, but Moderna will make the investment.